Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Source: SeekingAlpha
2026-07-02 07:30:00 ET
Read the full article on Seeking Alpha
For further details see:
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Solid Biosciences Inc.
NASDAQ: SLDB
SLDB Trading
-3.47% G/L:
$8.49 Last:
634,595 Volume:
$8.78 Open:
SLDB Latest News
May 07, 2026 08:00:00 am
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
$535,243,342
43,341,466
1.04%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Third FloorCharlestown
